Primary localized hyperhidrosis is a dermatological disorder that involves excessive sweat production without an underlying cause. The disease usually affects the axillae but can also involve palms, soles of the feet or face and causes major problems in many social situations with a negative impact on quality of life and mental health.

In this study, the investigators want to investigate the effect of microwave therapy (MiraDry®) on self-rated sweating, quality of life and anxiety in participants with severe axillary hyperhidrosis. The study also aims to evaluate the safety (side effects) of the method and long term effects over 1 year of follow upp.

The study is conducted during several visits or telephone follow-ups at the clinic over a period of 12 months and each patient receives a maximum of two treatments with MiraDry® (at 3-month intervals). 100 participants are planned to participate in the study.

The primary objective is to evaluate the effectiveness of the miraDry ® treatment measured by Hyperhidrosis Disease Severity Scale(HDSS).

Secondary objectives are to evaluate the side effects and the quality of Life by assessment of The Dermatology life Quality Index, The Hyperhidrosis Quality of Life Index, and Hospital Anxiety and Depression Scale.

Inclusion Criteria:

• This study will recruit participants diagnosed with primarily axillary hyperhidrosis
• Informed consent is required.
• HDSS 3 or 4 (the criteria used in Sweden to allow hospital-based intervention).

Exclusion Criteria:

Participants

• who are unable to provide informed consent,
• have known allergies to lidocaine, chlorhexidine, and/or epinephrine,
• are pregnant,
• are unable to take oral antibiotics or antiseptic washes,
• have heart pacemakers or other electronic device implants,
• who need supplemental oxygen,
• have had axillary surgery procedures for hyperhidrosis,
• with previous hidradenitis suppurativa or other local infections
• had previous cancer in the treated area are not eligible to participate in this study